Pembro monotherapy for participants with BCG–unresponsive HR NMIBC shows anti-tumour activity

Bookmark and Share
Published: 16 Mar 2023
Views: 46
Prof Andrea Necchi - The Vita-Salute San Raffaele University, Milan, Italy

Prof Andrea Necchi speaks to ecancer about the primary and subgroups analyses by PD-L1 status of cohort B of the phase 2 KEYNOTE-057 trial. The study investigated pembrolizumab monotherapy for participants with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC).

Prof Necchi explains the background and study design. The study found that after 45 months of follow-up, pembrolizumab showed anti-tumour activity in the total population and across PD-L1 subgroups in patients with BCG-unresponsive papillary-only HR NMIBC who declined or were ineligible for radical cystectomy.

Prof Necchi concludes by discussing the impact of these results on clinical practice.